In our Summary-data-based Mendelian Randomization (SMR) analysis, a significant association was identified between the PCSK9 drug target and the risk of cutaneous melanoma (OR, 1.44; 95% CI: 1.08–1.92; p = 0.011) as shown in Fig. 1. The gene discussed is PCSK9; the disease is cutaneous melanoma.